Estimate the annual commercial impact of two gaps: patients diagnosed late and patients who abandon treatment, using your own assumptions.
Percentage of patients diagnosed at a late stage, based on published clinical evidence (typically 20–60%).
Net annual revenue captured per patient receiving therapy.
AI-enabled early identification can recover up to 30% of late-diagnosed patients, based on conservative implementation assumptions.
Additional patients diagnosed earlier
120,000
Incremental annual revenue opportunity
$1,800,000,000
Based on 30% reduction in late diagnosis through AI prediction models
Estimates are based on epidemiological inputs and conservative AI adoption assumptions. Results are illustrative and should be validated against local market data.
Arkangel Insights shows physician questions, doubts and barriers by molecule, specialty, disease area and country. This tab models the commercial value of reaching late-diagnosed patients with your own inputs; the estimate is illustrative and should be validated with local market data.
The pharma industry loses $637B annually to medication non-adherence (IQVIA Institute, 2024). 27% of all new prescriptions and 31% of specialty oncology scripts are never filled (IQVIA Oncology Access Report, 2024). AI-powered patient support programs reduce therapy discontinuation by 14-20% (Johns Hopkins School of Public Health — Pharmaceutical PAP Analysis).
Schedule a personalized demo to see how Arkangel AI can transform your pharmaceutical operations.